Ipsen grants US botox rights to Medicis for $194M

26 March 2006

French drugmaker Ipsen has granted Aesthetica, a unit of USA-based Medicis, the rights to develop, distribute and commercialize its botulinum toxin product in the USA, Canada and Japan for esthetic use by physicians.

The product, which is commonly referred to as Reloxin in the US esthetic market and Dysport for medical and esthetic markets outside the USA, is not currently approved for use in America. Medicis has paid $90.1 million for the exclusive distribution rights and has agreed to an additional $26.5 million on successful completion of various clinical and regulatory milestones, $75.0 million on the product's approval by the Food and Drug Administration and $2.0 million on regulatory approval of the product in Japan, amounting to a total of $193.6 million. Ipsen will manufacture and provide the product for Medicis for the term of the deal, which extends to September of 2019.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight